Skip to main content
NCBI home page
Heart logoLink to Heart
. 1998 Dec;80(6):543–547. doi: 10.1136/hrt.80.6.543

Cholesterol lowering and coronary artery disease: mechanisms of risk reduction

R Archbold 1, A Timmis 1
PMCID: PMC1728874  PMID: 10065020

Full Text

The Full Text of this article is available as a PDF (94.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams M. R., Jessup W., Celermajer D. S. Cigarette smoking is associated with increased human monocyte adhesion to endothelial cells: reversibility with oral L-arginine but not vitamin C. J Am Coll Cardiol. 1997 Mar 1;29(3):491–497. doi: 10.1016/s0735-1097(96)00537-2. [DOI] [PubMed] [Google Scholar]
  2. Aikawa M., Rabkin E., Okada Y., Voglic S. J., Clinton S. K., Brinckerhoff C. E., Sukhova G. K., Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation. 1998 Jun 23;97(24):2433–2444. doi: 10.1161/01.cir.97.24.2433. [DOI] [PubMed] [Google Scholar]
  3. Ambrose J. A., Tannenbaum M. A., Alexopoulos D., Hjemdahl-Monsen C. E., Leavy J., Weiss M., Borrico S., Gorlin R., Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988 Jul;12(1):56–62. doi: 10.1016/0735-1097(88)90356-7. [DOI] [PubMed] [Google Scholar]
  4. Anderson T. J., Meredith I. T., Yeung A. C., Frei B., Selwyn A. P., Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995 Feb 23;332(8):488–493. doi: 10.1056/NEJM199502233320802. [DOI] [PubMed] [Google Scholar]
  5. Andrews T. C., Raby K., Barry J., Naimi C. L., Allred E., Ganz P., Selwyn A. P. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 1997 Jan 21;95(2):324–328. doi: 10.1161/01.cir.95.2.324. [DOI] [PubMed] [Google Scholar]
  6. Brown B. G., Zhao X. Q., Sacco D. E., Albers J. J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993 Jun;87(6):1781–1791. doi: 10.1161/01.cir.87.6.1781. [DOI] [PubMed] [Google Scholar]
  7. Brown G., Albers J. J., Fisher L. D., Schaefer S. M., Lin J. T., Kaplan C., Zhao X. Q., Bisson B. D., Fitzpatrick V. F., Dodge H. T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990 Nov 8;323(19):1289–1298. doi: 10.1056/NEJM199011083231901. [DOI] [PubMed] [Google Scholar]
  8. Buchwald H., Varco R. L., Matts J. P., Long J. M., Fitch L. L., Campbell G. S., Pearce M. B., Yellin A. E., Edmiston W. A., Smink R. D., Jr Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) N Engl J Med. 1990 Oct 4;323(14):946–955. doi: 10.1056/NEJM199010043231404. [DOI] [PubMed] [Google Scholar]
  9. Celermajer D. S. Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol. 1997 Aug;30(2):325–333. doi: 10.1016/s0735-1097(97)00189-7. [DOI] [PubMed] [Google Scholar]
  10. Chappell S. P., Lewis M. J., Henderson A. H. Effect of lipid feeding on endothelium dependent relaxation in rabbit aortic preparations. Cardiovasc Res. 1987 Jan;21(1):34–38. doi: 10.1093/cvr/21.1.34. [DOI] [PubMed] [Google Scholar]
  11. Chen L., Haught W. H., Yang B., Saldeen T. G., Parathasarathy S., Mehta J. L. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Am Coll Cardiol. 1997 Aug;30(2):569–575. doi: 10.1016/s0735-1097(97)00158-7. [DOI] [PubMed] [Google Scholar]
  12. Corsini A., Bernini F., Quarato P., Donetti E., Bellosta S., Fumagalli R., Paoletti R., Soma V. M. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology. 1996 Nov-Dec;87(6):458–468. doi: 10.1159/000177139. [DOI] [PubMed] [Google Scholar]
  13. Creager M. A., Selwyn A. When 'normal' cholesterol levels injure the endothelium. Circulation. 1997 Nov 18;96(10):3255–3257. [PubMed] [Google Scholar]
  14. Davies M. J., Bland J. M., Hangartner J. R., Angelini A., Thomas A. C. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J. 1989 Mar;10(3):203–208. doi: 10.1093/oxfordjournals.eurheartj.a059467. [DOI] [PubMed] [Google Scholar]
  15. Davies M. J., Richardson P. D., Woolf N., Katz D. R., Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993 May;69(5):377–381. doi: 10.1136/hrt.69.5.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Davies M. J. Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation. 1996 Oct 15;94(8):2013–2020. doi: 10.1161/01.cir.94.8.2013. [DOI] [PubMed] [Google Scholar]
  17. Davies M. J., Thomas A. C. Plaque fissuring--the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J. 1985 Apr;53(4):363–373. doi: 10.1136/hrt.53.4.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Dollery C. M., McEwan J. R., Henney A. M. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995 Nov;77(5):863–868. doi: 10.1161/01.res.77.5.863. [DOI] [PubMed] [Google Scholar]
  19. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J. 1983 Aug;50(2):127–134. doi: 10.1136/hrt.50.2.127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Freiman P. C., Mitchell G. G., Heistad D. D., Armstrong M. L., Harrison D. G. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res. 1986 Jun;58(6):783–789. doi: 10.1161/01.res.58.6.783. [DOI] [PubMed] [Google Scholar]
  21. Furchgott R. F., Zawadzki J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980 Nov 27;288(5789):373–376. doi: 10.1038/288373a0. [DOI] [PubMed] [Google Scholar]
  22. Fuster V., Badimon L., Badimon J. J., Chesebro J. H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med. 1992 Jan 23;326(4):242–250. doi: 10.1056/NEJM199201233260406. [DOI] [PubMed] [Google Scholar]
  23. Galis Z. S., Asanuma K., Godin D., Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation. 1998 Jun 23;97(24):2445–2453. doi: 10.1161/01.cir.97.24.2445. [DOI] [PubMed] [Google Scholar]
  24. Galis Z. S., Sukhova G. K., Lark M. W., Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994 Dec;94(6):2493–2503. doi: 10.1172/JCI117619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gurfinkel E., Bozovich G., Daroca A., Beck E., Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet. 1997 Aug 9;350(9075):404–407. doi: 10.1016/s0140-6736(97)07201-2. [DOI] [PubMed] [Google Scholar]
  26. Harrison D. G., Armstrong M. L., Freiman P. C., Heistad D. D. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest. 1987 Dec;80(6):1808–1811. doi: 10.1172/JCI113276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hoffman R., Brook G. J., Aviram M. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies. Atherosclerosis. 1992 Mar;93(1-2):105–113. doi: 10.1016/0021-9150(92)90204-t. [DOI] [PubMed] [Google Scholar]
  28. Ikari Y., Hara K., Tamura T., Saeki F., Yamaguchi T. Luminal loss and site of restenosis after Palmaz-Schatz coronary stent implantation. Am J Cardiol. 1995 Jul 15;76(3):117–120. doi: 10.1016/s0002-9149(99)80041-1. [DOI] [PubMed] [Google Scholar]
  29. John S., Schlaich M., Langenfeld M., Weihprecht H., Schmitz G., Weidinger G., Schmieder R. E. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation. 1998 Jul 21;98(3):211–216. doi: 10.1161/01.cir.98.3.211. [DOI] [PubMed] [Google Scholar]
  30. Lacoste L., Lam J. Y., Hung J., Letchacovski G., Solymoss C. B., Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995 Dec 1;92(11):3172–3177. doi: 10.1161/01.cir.92.11.3172. [DOI] [PubMed] [Google Scholar]
  31. Lee R. T., Kamm R. D. Vascular mechanics for the cardiologist. J Am Coll Cardiol. 1994 May;23(6):1289–1295. doi: 10.1016/0735-1097(94)90369-7. [DOI] [PubMed] [Google Scholar]
  32. Leung W. H., Lau C. P., Wong C. K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 1993 Jun 12;341(8859):1496–1500. doi: 10.1016/0140-6736(93)90634-s. [DOI] [PubMed] [Google Scholar]
  33. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995 Jun 1;91(11):2844–2850. doi: 10.1161/01.cir.91.11.2844. [DOI] [PubMed] [Google Scholar]
  34. Little W. C., Constantinescu M., Applegate R. J., Kutcher M. A., Burrows M. T., Kahl F. R., Santamore W. P. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988 Nov;78(5 Pt 1):1157–1166. doi: 10.1161/01.cir.78.5.1157. [DOI] [PubMed] [Google Scholar]
  35. Ludmer P. L., Selwyn A. P., Shook T. L., Wayne R. R., Mudge G. H., Alexander R. W., Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986 Oct 23;315(17):1046–1051. doi: 10.1056/NEJM198610233151702. [DOI] [PubMed] [Google Scholar]
  36. Lüscher T. F., Barton M. Biology of the endothelium. Clin Cardiol. 1997 Nov;20(11 Suppl 2):II–3-10. [PubMed] [Google Scholar]
  37. Muhlestein J. B., Anderson J. L., Hammond E. H., Zhao L., Trehan S., Schwobe E. P., Carlquist J. F. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation. 1998 Feb 24;97(7):633–636. doi: 10.1161/01.cir.97.7.633. [DOI] [PubMed] [Google Scholar]
  38. O'Driscoll G., Green D., Taylor R. R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997 Mar 4;95(5):1126–1131. doi: 10.1161/01.cir.95.5.1126. [DOI] [PubMed] [Google Scholar]
  39. Pech-Amsellem M. A., Myara I., Storogenko M., Demuth K., Proust A., Moatti N. Enhanced modifications of low-density lipoproteins (LDL) by endothelial cells from smokers: a possible mechanism of smoking-related atherosclerosis. Cardiovasc Res. 1996 Jun;31(6):975–983. [PubMed] [Google Scholar]
  40. Richardson P. D., Davies M. J., Born G. V. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989 Oct 21;2(8669):941–944. doi: 10.1016/s0140-6736(89)90953-7. [DOI] [PubMed] [Google Scholar]
  41. Rosenson R. S., Tangney C. C. Beneficial effects of statins. Lancet. 1996 Dec 7;348(9041):1583–1583. doi: 10.1016/S0140-6736(05)66194-6. [DOI] [PubMed] [Google Scholar]
  42. Sacks F. M., Pfeffer M. A., Moye L. A., Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M., Wun C. C. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 Oct 3;335(14):1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]
  43. Shiomi M., Ito T., Tsukada T., Yata T., Watanabe Y., Tsujita Y., Fukami M., Fukushige J., Hosokawa T., Tamura A. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1938–1944. doi: 10.1161/01.atv.15.11.1938. [DOI] [PubMed] [Google Scholar]
  44. Small D. M., Bond M. G., Waugh D., Prack M., Sawyer J. K. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 1984 Jun;73(6):1590–1605. doi: 10.1172/JCI111366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Stamler J., Wentworth D., Neaton J. D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986 Nov 28;256(20):2823–2828. [PubMed] [Google Scholar]
  46. Steinberg D., Parthasarathy S., Carew T. E., Khoo J. C., Witztum J. L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989 Apr 6;320(14):915–924. doi: 10.1056/NEJM198904063201407. [DOI] [PubMed] [Google Scholar]
  47. Tsuda Y., Satoh K., Kitadai M., Takahashi T., Izumi Y., Hosomi N. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis. 1996 May;122(2):225–233. doi: 10.1016/0021-9150(95)05757-9. [DOI] [PubMed] [Google Scholar]
  48. Vita J. A., Treasure C. B., Nabel E. G., McLenachan J. M., Fish R. D., Yeung A. C., Vekshtein V. I., Selwyn A. P., Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990 Feb;81(2):491–497. doi: 10.1161/01.cir.81.2.491. [DOI] [PubMed] [Google Scholar]
  49. Vos J., de Feyter P. J., Simoons M. L., Tijssen J. G., Deckers J. W. Retardation and arrest of progression or regression of coronary artery disease: a review. Prog Cardiovasc Dis. 1993 May-Jun;35(6):435–454. doi: 10.1016/0033-0620(93)90028-c. [DOI] [PubMed] [Google Scholar]
  50. Watts G. F., Lewis B., Brunt J. N., Lewis E. S., Coltart D. J., Smith L. D., Mann J. I., Swan A. V. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) Lancet. 1992 Mar 7;339(8793):563–569. doi: 10.1016/0140-6736(92)90863-x. [DOI] [PubMed] [Google Scholar]
  51. Williams J. K., Sukhova G. K., Herrington D. M., Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol. 1998 Mar 1;31(3):684–691. doi: 10.1016/s0735-1097(97)00537-8. [DOI] [PubMed] [Google Scholar]
  52. Ylä-Herttuala S., Palinski W., Rosenfeld M. E., Parthasarathy S., Carew T. E., Butler S., Witztum J. L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989 Oct;84(4):1086–1095. doi: 10.1172/JCI114271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Zeiher A. M., Drexler H., Wollschläger H., Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 1991 Feb;83(2):391–401. doi: 10.1161/01.cir.83.2.391. [DOI] [PubMed] [Google Scholar]
  54. Zeiher A. M., Schächinger V., Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation. 1995 Sep 1;92(5):1094–1100. doi: 10.1161/01.cir.92.5.1094. [DOI] [PubMed] [Google Scholar]
  55. van Boven A. J., Jukema J. W., Zwinderman A. H., Crijns H. J., Lie K. I., Bruschke A. V. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation. 1996 Oct 1;94(7):1503–1505. doi: 10.1161/01.cir.94.7.1503. [DOI] [PubMed] [Google Scholar]
  56. van der Wal A. C., Becker A. E., van der Loos C. M., Das P. K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994 Jan;89(1):36–44. doi: 10.1161/01.cir.89.1.36. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES